UK markets close in 1 hour 4 minutes

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.9339+0.0977 (+11.68%)
As of 04:05PM BST. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • B
    Blockbuster
    (CING) $1.27 --MC $13 mil ....BIG Phase 3 Asset and imminent data readout coming next week = $$$$$$$$$$
  • M
    Mike
    Musing. Expecting proxy ballots any day now for TYME & SYROS retail stockholders.Also thinking the election to be simultaneous. The pps for both have been pretty flat. #$%$ Y-on-Y for all retailers. Beneficial holders have all signed off by SEC filings. One big family, waiting on consummation.Thinking the timing on coming events have to be simultaneous to avoid wild PPS swings from day-traders which would skew the pre-agreed terms:Excerpt ?July 5th Announcement (SYROS)~~~~~~~~~~~~~~~~~Upon the closing of the Merger, the Company expects to issue approximately 74.3 million shares of the Company?s common stock to Tyme stockholders, Assuming that Tyme net cash as of the closing of the Merger is approximately $60 million and Tyme stockholders are expected to receive approximately 0.4312 shares of the Company?s common stock for each share?.~~~~~~~~~~~~~~~~~PPS of each July 5th ?17tt?-------------------Tyme .292 ?.296Syrs .87?.93Syros is set to pick up those cash reserves, which are expected to total $60 million after costs, by giving stock to Tyme shareholders. In conjunction with the merger, Syros has put together a private investment round. Syros? founding investor Flagship Pioneering is participating in the $130 million financing with Avidity Partners, Deep Track Capital, Bain Capital Life Sciences, Invus and other backers. Link:https://www.fiercebiotech.com/biotech/buying-tyme-syros-inks-190m-merger-flagship-backed-financing-extend-cash-runway-2025GLTUA
    Syros Pharmaceuticals has bought itself that most prized of assets in today’s biotech market: time. | Syros Pharmaceuticals has bought itself that most prized of assets in today’s biotech market: time. By merging with the floundering Tyme Technologie
    Syros Pharmaceuticals has bought itself that most prized of assets in today’s biotech market: time. | Syros Pharmaceuticals has bought itself that most prized of assets in today’s biotech market: time. By merging with the floundering Tyme Technologie
    www.fiercebiotech.com
  • D
    Daniel
    Why is $SYRS SP dropping right after the $TYME acquisition?
  • M
    Morten
    After private placement, cash from TYME, and 74,3 mill new shares there will be between 1,6 and 1,98 cash per share.
  • K
    Kuryo193
  • j
    jerzy
    SYRS made an excellent deal by merging with TYME . 240 million on hand and enough to go into 2025 . Getting pipe line with multy cancer, and covid potencial drugs ,this is huge. Few read out by end of this year .
    Getting foot into Mayo and Georgetown University is a huge jump. Patience will pay handsomely here.
  • j
    jerzy
    Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: Rationale Behind the Upgrade
  • M
    Martin
    What's the basis for the Jalper Sadeh investigation into whether this is good value for Syros share holders? Maybe some major shareholder asked them to, i guess?
  • M
    Morten
    Money in the box until 2025, way to go, cool.
  • j
    jerzy
    Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
  • j
    jerzy
    This is a great deal. SYRS is adding tremendous pipeline . Fake lawsuit scam. They want to scare small retailers and buy cheap shares. Hold on guys, patience here will reward you.
  • j
    jerzy
    Zacks rating STRONG BUY, only 5% stocks get this rating. Hold on guys this is a diament .
  • M
    Michael
    Congrads to the new bagholders who bought in the $1.40 range after hours, nothing like a 40% shellacking to start the day lololol
  • j
    jerzy
    those who are selling should never be in SM .
  • j
    jerzy
    All manipulation. Im not worry about daily movement in sp . I look at this Company with vision and what the future can bring, and the future to me looks very bright, especially now after adding all pipeline and some of the biggest and best names liky Mayo Clinic and Georgtown Univ. from TYME.
    250 millions in the bank ,and enough to go into 2025 .Do anyone think all those Investors who are putting on the table 130 million are doing this to lose money .Because I don't think so . I really don't care what others say. Im a patient man and will wake till I multiply my money.
  • M
    Mike
    Please allow me to introduce myself,
    I'm a mN of taste and hoping for means
    Your parent company is engaged to mine. So we get related. You all already had your annual vote, before the ANNOUNCEMENT.

    Ours normally in August. Waiting on the proxy balloy now. With the full proposal on EDGAR, the Merger info will be on the proxy ballot. Our board and founders will pass it.

    Retail holders a minority. We're in the second half of a non-compliant year. The past board halte two promising trials (Prostate and breast). All funds went to 2 trials on Metastatic Pancreatic. Both cut in 3d phase.

    Back in breast. Small leg in sarcoma still active. Impressed with list of big players in your PIPE financing.

    Your trials. And SY-products?? Just a layman. Won't pretend I understand them.

    GLTUA
  • a
    art
    any thoughts on why we are up 18% today?
  • j
    jerzy
    The good news is that someone bought akll those shares . Today was a poker game between 2 heavy weights they traded between themself and triggered all stop loses so they could load all they wanted.
    Next week we are going to $5.0
  • V
    V.
    IMHO this stock has bottomed out enough in the last couple of weeks and should now begin to rise again.